Latest News and Press Releases

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone...

Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targetsOBT to receive up to US$36 million...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based...

CMO Dr. Harald Haeske to present innovative approaches for combining ADCs with immune checkpoint inhibitors to enhance therapeutic efficacyOBT will also present insights on its target discovery...

Oxford, UK and San Jose, California, 22 July 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based...

OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...

OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors Oxford, UK,...

BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery...

BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets ...

Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...